129 related articles for article (PubMed ID: 32467248)
21. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
23. Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.
Ho CH; Silva AA; Giles JT; Bathon JM; Solomon DH; Liao KP; Ho IC
Arthritis Rheumatol; 2021 Jun; 73(6):1086-1087. PubMed ID: 33426780
[No Abstract] [Full Text] [Related]
24. Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect Evaluation.
Kraev K; Geneva-Popova M; Popova V; Popova S; Maneva A; Batalov A; Stankova T; Delcheva G; Stefanova K
Folia Med (Plovdiv); 2020 Jun; 62(2):282-289. PubMed ID: 32666748
[TBL] [Abstract][Full Text] [Related]
25. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature.
Ohmura SI; Homma Y; Hanai S; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Jan; 7(1):9-13. PubMed ID: 35285489
[TBL] [Abstract][Full Text] [Related]
26. Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab.
Dubiel-Braszczok B; Nowak K; Owczarek A; Engelmann M; Gumkowska-Sroka O; Kotyla PJ
Curr Pharm Des; 2022; 28(24):2029-2037. PubMed ID: 35638285
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
28. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
29. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K
Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355
[TBL] [Abstract][Full Text] [Related]
31. The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.
Berkhout LC; l'Ami MJ; Krieckaert CLM; Vogelzang EH; Kos D; Nurmohamed MT; Wolbink GJ; Rispens T
Rheumatology (Oxford); 2020 Jul; 59(7):1703-1708. PubMed ID: 31691828
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis.
Lee YH; Woo JH; Rho YH; Choi SJ; Ji JD; Song GG
Rheumatol Int; 2008 Apr; 28(6):553-9. PubMed ID: 17943257
[TBL] [Abstract][Full Text] [Related]
33. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Emery P; Horton S; Dumitru RB; Naraghi K; van der Heijde D; Wakefield RJ; Hensor EMA; Buch MH
Ann Rheum Dis; 2020 Apr; 79(4):464-471. PubMed ID: 31996367
[TBL] [Abstract][Full Text] [Related]
34. Seropositivity of Rheumatoid Arthritis Specific Tests in a Patient With Nephrotic Syndrome: Successful Treatment With Rituximab.
Mirzaei A; Ataeipoor Y; Asgari M; Zabihiyeganeh M
Iran J Kidney Dis; 2017 Nov; 11(6):467-468. PubMed ID: 29190608
[TBL] [Abstract][Full Text] [Related]
35. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
[TBL] [Abstract][Full Text] [Related]
36. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study.
Santos-Moreno P; Sánchez G; Castro C
Medicine (Baltimore); 2019 Feb; 98(5):e14181. PubMed ID: 30702571
[TBL] [Abstract][Full Text] [Related]
37. Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study).
Migliore A; Bizzi E; Massafra U; Vacca F; Martin Martin LS; Ferlito C; Podestà E; Granata M; Laganà B
Int J Immunopathol Pharmacol; 2010; 23(3):783-90. PubMed ID: 20943048
[TBL] [Abstract][Full Text] [Related]
38. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.
Aaltonen KJ; Joensuu JT; Pirilä L; Kauppi M; Uutela T; Varjolahti-Lehtinen T; Yli-Kerttula T; Isomäki P; Nordström D; Sokka T
Scand J Rheumatol; 2017 Sep; 46(5):359-363. PubMed ID: 27931158
[TBL] [Abstract][Full Text] [Related]
39. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
40. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A
Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
